Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects

Inclusion Criteria: * Years 20-45 * Body weight ≥ 50kg and 18 ≤ BMI ≤ 29kg/m2 * volunteer Exclusion Criteria: * Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease * Subject with symptoms of acute disease within 28days prior to study medication dosing * Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug * Subject with clinically significant active chronic disease * Subject with any of the following conditions in laboratory test i. AST(sGOT) or ALT(sGPT) \> Upper normal limit × 1.5 ii. Total bilirubin \> Upper normal limit × 1.5 iii. renal failure with Creatinine clearance \< 50mL/min * Clinically significant hypotension when screening period (SBP \< 100mmHg, DBP \< 60mmHg) * Positive test results for HBs Ab, HCV Ab, Syphilis regain test * Use of any prescription medication within 14 days prior to study medication dosing * Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing * Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug) * Subject with known for hypersensitivity reaction to S-amlodipine, amlodipine and valsartan and dihydropyridine derivatives * Subject who is not able to taking the institutional standard meal * Subjects with whole blood donation within 60days, component blood donation within 20days * Subjects receiving blood transfusion within 30days prior to study medication dosing * Participation in any clinical investigation within 60days prior to study medication dosing * Continued excessive use of caffeine (caffeine \> five cups/day), alcohol(alcohol\>30g/day) and severe heavy smoker (cigarette \> 10 cigarettes per day) * Subject who has been taken meal which affect on the absorption, distribution, metabolism, excretion of drug, especially grapefruit juice * Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 28days prior to study medication dosing * Continued serum potassium concentration abnormal status (on baseline visit, \< 3.5mEq/L or \> 5.5mEq/L) * Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator